Abstract
Purpose
To present the current evidence and the development of studies in recent years on the management of extragonadal germ cell tumors (EGCT).
Methods
A systematic literature search was conducted in Medline and the Cochrane Library. Studies within the search period (January 2010 to February 2021) that addressed the classification, diagnosis, prognosis, treatment, and follow-up of extragonadal tumors were included. Risk of bias was assessed and relevant data were extracted in evidence tables.
Results
The systematic search identified nine studies. Germ cell tumors (GCT) arise predominantly from within the testis, but about 5% of the tumors are primarily located extragonadal. EGCT are localized primarily mediastinal or retroperitoneal in the midline of the body. EGCT patients are classified according to the IGCCCG classification. Consecutively, all mediastinal non-seminomatous EGCT patients belong to the “poor prognosis” group. In contrast mediastinal seminoma and both retroperitoneal seminoma and non-seminoma patients seem to have a similar prognosis as patients with gonadal GCTs and metastasis at theses respective sites. The standard chemotherapy regimen for patients with a EGCT consists of 3–4 cycles (good vs intermediate prognosis) of bleomycin, etoposid, cisplatin (BEP); however, due to their very poor prognosis patients with non-seminomatous mediastinal GCT should receive a dose-intensified or high-dose chemotherapy approach upfront on an individual basis and should thus be referred to expert centers Ifosfamide may be exchanged for bleomycin in cases of additional pulmonary metastasis due to subsequently planned resections. In general patients with non-seminomatous EGCT, residual tumor resection (RTR) should be performed after chemotherapy.
Conclusion
In general, non-seminomatous EGCT have a poorer prognosis compared to testicular GCT, while seminomatous EGGCT seem to have a similar prognosis to patients with metastatic testicular seminoma. The current insights on EGCT are limited, since all data are mainly based on case series and studies with small patient numbers and non-comparative studies. In general, systemic treatment should be performed like in testicular metastatic GCTs but upfront dose intensification of chemotherapy should be considered for mediastinal non-seminoma patients. Thus, EGCT should be referred to interdisciplinary centers with utmost experience in the treatment of germ cell tumors.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Germ cell tumors (GCT) arise predominantly from within the testis, but an important subset of about 5% of the tumors are primarily located extragonadal with no testicular primary tumor being detectable [1].
Extragonadal germ cell tumors (EGCTs) are a heterogeneous group of tumors of neoplastic germ cells arising from extragonadal anatomical locations located in the midline of the body. Primary EGCT are considered a special subgroup of GCT with a poorer prognosis due to larger volume and different biology. They result from malignant transformation of germ cells that were either maldistributed during embryonic development or germ cells that naturally occur to control immunological processes or other organ functions at extragonadal locations [1].
EGCTs include seminomatous tumors (classical seminoma), and non-seminomatous tumors (embryonal carcinoma, teratoma, yolk sac carcinoma, chorioncarcinoma).
Histological, serological and cytogenetic characteristics of EGCTs are similar to those of primary testicular GCT, but differences in clinical behavior suggest that gonadal and extragonadal tumors are biologically different [1].
EGCTs have significantly larger tumor masses at diagnosis. There is a predominance for the occurrence in the anterior mediastinum, especially of non-seminomatous subtypes. A association of EGCTs has been described with Klinefelter syndrome [2]. Furthermore, about 5–10% of patients with non-seminomatous EGCTs of the mediastinum are at risk for the development of acute leukemias, which are not therapy induced but rather biologically associated [1, 3]. These differences may account for the somewhat poorer outcome of some subgroups of patients with EGCTs.
The aim is to present the current evidence on classification, diagnosis, prognosis, therapy and follow-up of EGCT and to highlight recent studies in this special subfield of GCT.
Methods
This work is based on a former systematic literature search that was conducted for the elaboration of the first German clinical practice guideline [4]. Here, we updated a systematic literature search using the biomedical databases Medline (Ovid) and the Cochrane Library to identify studies on classification, diagnosis, prognosis, treatment and follow-up of EGCT. We considered studies that were published between January 2010 to February 2021 with available full texts publications in English or German language. Study selection, data extraction and risk of bias assessment was done by one reviewer. Relevant and well-known articles published before the search date of 2010 were additionally used to supplement the evidence base, as the cut-off of the year 2010 was formerly chosen due to limited resources in the guideline development process. The Oxford 2009 criteria were used to rate the level of evidence of included studies [5]. Two reviewers assessed the risk of bias in cohort studies with the Scottish Intercollegiate Guidelines Network (SIGN) checklist for cohort studies [6], prognostic studies with the QUIPS tool and for case series [7], we used a self-developed tool based on the quality appraisal checklist of Guo et al. [8]. This systematic review adheres to the recommendations of the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-analysis) guidelines [9].
Results
The systematic literature search identified nine studies (see Fig. 1). Four of these studies addressed prognostic [10,11,12,13] and five therapeutic questions [14,15,16,17,18]. All treatment studies identified were retrospective, whereas four were case series and one was a cohort study (Table 1). Data on ECGT are limited, since all data mainly based on case series, studies with small patient numbers and no comparative prospective studies. Risk of bias of included studies ranged from low to high risk of bias. Missing control of possible confounders, missing information on patient inclusion and insufficient description of interventions were mostly the reasons for assigning a high-risk judgement to a study.
Localizations of EGCTs
EGCTs are localized primarily mediastinal or retroperitoneal, but also at any other site along the midline except the testis [19]. The anterior mediastinum (50–70%) and retroperitoneum (30–40%) represent the most common locations of EGCT [20]. Less common sites of origin for EGCTs are the pineal gland (glandula pienalis), os sacrum, prostate, orbita, urinary bladder, or liver (Table 2). Epidemiological data from Germany show a high preference for the brain, pituitary and pineal gland with about 40% of patients (61 of 157 patients) [21]. According to a study by the National Cancer Register of Finland, the incidence of EGCTs is about 0.18/100.000 [22].
Mediastinal EGCTs
In a case series, 320 male patients with confirmed primary mediastinal EGCTs were reported [23]. The histological discrimination between pure seminoma, non-seminoma and teratoma is very important. Teratomas and pure seminomas are the most common histological subtypes of mediastinal EGCTs. Mature mediastinal teratomas are considered “benign” and are treated by surgical resection alone, as chemotherapy or radiotherapy are not effective. About 43% of all mediastinal tumors harbor parts of a teratoma [24]. About 63% of them are mature teratomas, 37% are teratomas with malignant transformations, for example GCT plus sarcoma components or adenocarcinoma components [24]. Teratomas with malignant GCT components, for example seminoma, embryonal carcinoma or yolk sac tumor are considered as malignant non-seminomatous EGCTs. Unlike conventional GCTs, which usually respond favorable to platinum-based chemotherapy, teratoma with malignant transformation is a very aggressive tumor that is resistant to chemotherapy and needs extended surgical treatment [4, 25].
Mediastinal EGCTs are differentiated into seminomas and non-seminomas. Among mediastinal EGCTs, seminomas account for 40% of the non-teratoma EGCT and are thereby more common than in EGCTs in general, where they account for only 20–24% of the tumors. In a large international case series of 635 patients with mediastinal and retroperitoneal EGCTs, 104 patients showed pure seminomas and 524 had non-seminomatous tumors [26]. In contrast to testicular non-seminomatous GCTs, mediastinal non-seminomatous EGCTs contain embryonal carcinoma less frequent and yolk sac tumor components more frequent. In a series of 64 patients, histology revealed a pure yolk sac tumor in 60% of the patients, a chorionic carcinoma in 12%, and a pure embryonic carcinoma in about 9% of the patients [27].
Retroperitoneal EGCTs
Retroperitoneal EGCTs have a clinical behavior very similar to that of testicular GCTs [24]. The genesis of retroperitoneal GCTs is still under debate [20]. Undisputed is an association between a premalignant testicular lesion and retroperitoneal EGCT. The differential diagnosis to “burnt out” EGCT of the testis with retroperitoneal metastasis is difficult. A retrospective analysis from Switzerland of 26 patients with a retroperitoneal EGCT discovered pathological findings on clinical examination of the testes in 11 patients (42%) [28]. 14 patients (54%) showed a testicular atrophy and/or induration, one patient had an enlarged testicle. Ultrasound examination demonstrated a suspicious lesion in every patient. Finally, pathological review of the testicular tissue was performed for 25 of the 26 patients. They revealed scar tissue in 12 patients (48%), intratubular neoplasia in 4 (16%) and vital malignant tumor in 3 patients (12%). Conclusively, the authors postulated that primary EGCT in the retroperitoneum are very likely a rare or non-existing entity and should be considered as metastases of a viable or burned-out testicular cancer until proven otherwise [28].
Other rare localizations of EGCTs
Less frequent sites of EGCT are the pineal gland (glandula pienalis), os sacrum, prostate, orbita, urinary bladder or liver [19]. Epidemiological data from Germany indicate a high preference for the brain, the pituitary and pineal gland accounting for 40% of the patients (61 of 157 patients) [21]. In adults, mature teratomas are the most common presentation of sacrococcygeal EGCTs, but GCTs without teratomatous components have also been documented [29].
Pathology of EGCTs**
Primary EGCTs are considered a special subgroup of GCTs. They result from malignant transformation of germ cells that were either maldistributed during embryonic development or from germ cells that naturally occur at extragonadal sites for the purpose of controlling immunological processes or other organ functions [30, 31].
In principle, the same histological subtypes are present in EGCT as in testicular localized GCTs (seminomas and non-seminomatous EGCT). EGCTs include seminomatous tumors (classical seminoma), and non-seminomatous tumors, including embryonal carcinoma, teratoma (mature or immature), yolk sac carcinoma and chorioncarcinoma. EGCTs constituted by two or more histotypes are referred to as mixed germ cell tumors, which classified as non-seminomatous tumors. In mediastinal EGCT, seminomatous tumor components and teratoma components are frequently detectable [26, 27].
There is a clear association between EGCT and Klinefelter’s syndrome, a male genetic disorder characterized by the 47, XXY karyotype, small and soft testis, sterility, eunuchoid habitus, gynecomasty, high levels of FSH and a 20-fold increased risk for breast cancer. Regarding the increased risk of EGCT in Klinefelter´s patients, it is still unclear whether the development of GCTs in patients with Klinefelter’s syndrome is the result of a primary genetic abnormality or of an abnormal hormonal milieu that primes premalignant tumor cells into malignant tumor development [1].
In addition, an increased rate of yolk sac components, elevated AFP levels, and TP53 aberrations are observed in EGCTs compared to testicular GCTs [32].
Primary mediastinal non-seminomatous EGCTs can be the origin of hematologic neoplasms with an incidence of 5–10% [33]. These hematological neoplasms frequently contain an isochromosome 12p, which is the cytogenetic hallmark of GCTs and confirms the common biological background of both the EGGCT and the hematological neoplasia [34]. Hematologic malignancies associated with primary mediastinal non-seminomatous germ cell tumors are mainly disorders of the megakaryocyte lineage characterized as acute mega-karyoblastic leukemia (AML-M7) and myelo-dysplastic syndrome with abnormal megakaryocytes [33].
Clinical symptoms and diagnosis
EGCTs often present only at advanced stages due to tumor-related symptoms, but they also occur as incidental findings during diagnostic or other therapeutic interventions. The clinical presentation of EGCT varies widely. Avery advanced cases of mediastinal EGCT may present with pulmonary symptoms or venous compression syndromes (including superior vena cava syndrome). When the EGCT is primarily located in the retroperitoneum, abdominal pain, back pain, weight loss, inferior vena cava thrombosis, or hydronephrosis are the main clinical presentations.
The most conclusive data regarding clinical symptoms were shown in 2012 in the largest published series of EGCTs with 635 patients by Bokemeyer et al. [26]. Patients with mediastinal EGCT had in particular dyspnea (25%), chest pain (23%) and cough (17%) at initial presentation, followed by fever (13%), weight loss (11%), vena cava occlusion syndrome and fatigue/weakness (6%). Less frequent symptoms than expected were enlarged cervical lymph nodes (2%), hemoptysis, hoarseness and dysphagea (1% each).
In patients with a primary retroperitoneal EGCT, the main symptoms were abdominal (29%) and back pain (14%), followed by weight loss (9%), fever (8%), vena caval or other thrombosis (9%), palpable abdominal tumor (6%), enlarged cervical lymph nodes (4%), scrotal edema (5%), gynecomastia and dysphagea (3%).
The symptoms of EGCT patients are caused by the growing tumor mass. After appropriate imaging with ultrasound and computed tomography/magnetic resonance imaging (CT/MRI), the diagnosis should be confirmed histologically. Depending on the localization, this can be performed by fine-needle aspiration cytology, percutaneous biopsy or specimen resection during mediastinoscopy/laparoscopy [1]. In addition, the evaluation of serum tumor markers (AFP, beta-hCG, LDH) is required for the correct diagnosis and classification of EGCTs according to the International Germ Cell Cancer Collaborative Group (IGCCCG) [35].
The role of FDG-PET-CT in the primary diagnosis of EGCT is unclear. However, in evaluating the success of first-line systemic therapy, FDG-PET may have a decisive value. Additionally, Buchler et al. showed that a negative FDG-PET after the completion of EGCT treatment was a powerful predictor of long-term survival with 100% of the patients surviving three years and 89% surviving five years after diagnosis [11].
Retroperitoneal EGCTs are often associated with a "burned-out" tumor of the testis, whereas in mediastinal EGCTs, this is extremely rare [36]. The question whether a clinical and sonographic non-suspicious testis has to undergo histological assessment is still controversial. In the largest international EGCT series of Bokemeyer et al., about 11% of the patients underwent a testicular biopsy. In 3% of the cases, a Sertoli cell-only syndrome was diagnosed, 31% had atrophic or fibrotic testicular tissue and only 9% germ cell neoplasia in situ (GCNIS) lesions. Current guidelines do not recommend the removal of the testis as long as the ultrasound findings are normal [4].
In 2001, Hartmann et al. observed that metachronous testicular GCTs most commonly occurred in seminomatous EGCTs with a cumulative risk of 10% within 10 years [34]. This risk appeared to be higher than in other series of metastatic GCTs. Thus, a routine testicular biopsy in EGCT patients was discussed. However, these secondary testicular tumors are quite easy to detect and, especially in the case of seminoma, highly curable. Therefore, a routine bilateral testicular biopsy in EGCT patients cannot be routinely justified. However, regular ultrasound of the testis during follow-up seems reasonable. Due to the limited number of cases, clear evidence-based recommendations cannot be given regarding the discussed issues.
Classification
In the largest international analysis of EGCTs, patients with seminomatous EGCTs with the primary localization in the mediastinum and retroperitoneum had an equivalent prognosis to patients with primary testicular seminoma according to the IGCCCG classification (Table 3) and similar metastatic locations [26, 37]. In spring 2021, the IGCCCG update consortium improved the 1995 classification by developing and independently validating a more detailed prediction model. This model identified a new cut-off of lactate dehydrogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional adverse prognostic factors. Overall, the long-term outcome of patients from all prognostic categories was improved compared to 1995, however, mediastinal non-seminoma remained a clear criterion for “poor prognosis”. An online calculator is provided (https://www.eortc.org/IGCCCG-Update) [37].
The same parameters which identified patients with testicular seminomatous tumors, also predicted the individual prognosis in seminomatous tumors of primary extragonadal origin. Therefore, patients with seminomatous EGCTs should be classified as either "good prognosis" or "intermediate prognosis" according to IGCCCG and treated accordingly.
In the case series reported, non-seminomatous EGCTs had a worse prognosis than seminomatous EGCTs with a 5-year survival rate of 62% for retroperitoneal and 45% for mediastinal non-seminomatous EGCTs [26]. The analysis clearly indicated that mediastinal EGCTs belong to the poor prognosis group even if they otherwise fulfilled the IGCCCG criteria of good or intermediate prognosis. All patients with mediastinal non-seminomatous EGCT are classified as poor prognosis irrespective of further metastatic spread or serum tumor marker levels [38].
Patients with retroperitoneal non-seminomatous EGCTs are classified according to the serum tumor marker constellation of the IGCCCG classification and are treated analogously to metastatic testicular non-seminomatous GCTs. Several other studies corroborated these results [39,40,41,42].
Treatment
Seminomatous EGCTs
Patients with seminomatous EGCTs should be treated according to the IGCCCG classification prognostic group, with three cycles of bleomycin, etoposide, cisplatin (BEP) for good prognosis and four cycles of BEP for intermediate prognosis patients. An alternative chemotherapy regimen in case of contraindications to bleomycin in good prognosis patients is four cycles of etoposide, cisplatin or substituting bleomycin by ifosfoamide if a subsequent pulmonary operation is planned [41, 4]
EGCT patients with pure seminomatous germ cell tumors have a better prognosis than non-seminomas, especially because seminoma cells are highly susceptible to cisplatin-based chemotherapy and ionizing radiation. A residual tumor resection is not routinely required. In three retrospective studies of patients with mediastinal seminomatous EGCTs (case numbers ranging from 7 to 17), 5-year overall survival (OS) rates of 71% and 100% were reported [15, 16, 18].
In a case series of 52 patients with a retroperitoneal pure seminoma and 51 patients with a mediastinal pure seminoma, the 5-year progression-free survival (PFS) and the 5-year OS rates were 87% and 90%, respectively [43]. 75% of the patients were successfully treated with chemotherapy alone.
Similar to the therapy of testicular CS II GCTs, retroperitoneal seminomatous EGCTs can be treated with radiotherapy if tumor extension is limited. Unfavourable prognostic factors for pure seminomas are the presence of liver metastases or metastases in two or more different organs; however, this leads to a classification of intermediate prognosis in these cases, as seminomas, both metastatic from testicular origin or extragonadal are never categorized as IGCCCG “poor prognosis” [43].
Non-seminomatous EGCTs
The standard chemotherapy regimen for patients with a mediastinal non-seminomatous EGCT consists of four cycles of cisplatin-based combination chemotherapy either BEP or PEI. Only few studies with limited numbers of cases have been reported on primary mediastinal non-seminomatous EGCTs [12,13,14, 18, 42]. In the study by De Latour et al., all 21 patients were treated with first-line chemotherapy, and 52% of patients required second-line chemotherapy. The 5-year OS of patients with tumors confined to the mediastinum was 50% and of patients with extra-mediastinal involvement 27% [14]. A Memorial Sloan Kettering Cancer Center series reported on 57 resected patients with primary mediastinal non-seminomatous GCT, 54 of whom were pretreated with platinum-based chemotherapy [17]. Median OS was 31.5 months, and preoperatively normalized or reduced serum tumor markers after chemotherapy were the strongest predictors of improved survival [17].
In non-seminomatous EGCT, residual tumor resection (RTR) should be performed analogously to metastatic testicular GCT after the completion of chemotherapy. In primary mediastinal non-seminomatous EGCT resection of all visible residuals (even < 1 cm) should be aimed for, and post-chemotherapy elevated serum tumor markers should not discourage surgery. In this context, some studies performed multivariate analyses, all of which emphasized surgical therapy after initial systemic therapy as an important prognostic factor [12, 13].
No prospective studies have investigated the role of high-dose chemotherapy in the first-line treatment of extragonadal germ cell tumors so far. In a meta-analysis of 524 patients with non-seminomatous germ cell tumors in 2002 by Bokemeyer et al., 59 patients (13%) were treated with high-dose chemotherapy [26]. In the univariate analysis, high-dose chemotherapy was not a significant prognostic factor for improved survival. In contrast, in another study [44] with 64 EGCT patients out of 235 patients with mainly poor prognosis criteria (IGCCCG) treated with initial high-dose chemotherapy, 5-year overall survival was reported to be higher compared to standard-dose platinum-based combination chemotherapy with four cycles of BEP (82% versus 71%) [44]. Due to very poor prognosis of patients with primary mediastinal EGCT, a dose-intensified or high-dose chemotherapy should be chosen primarily and is recommended in the German national S3 guideline for testicular cancer.
In contrast to all other non-seminomatous EGCTs, mature teratomas are resistant to chemotherapy. If there is clear histologic evidence of a mature teratoma and no elevation of serum tumor markers for GCTs, surgical resection of the EGCT is the best therapeutic option.
In summary, all patients with mediastinal non-seminomatous EGCTs are classified in the poor prognosis group. Furthermore, the chemosensitivity of primary mediastinal non-seminomatous EGCTs appears to be lower compared to testicular and/or retroperitoneal EGCT, as vital carcinoma portions are frequently found in resected post-chemotherapeutic ETGC mediastinal residuals [14, 45]. Accordingly, upfront intensification of therapy with high-dose chemotherapy and surgical resection of all visible residuals after chemotherapy should be preferred. The chance of cure even when employing high-dose therapy plus autologous stem cell support as salvage therapy is very limited with long-term survival of only 11% in relapsed mediastinal EGCT patients [46]. The complex management of these patients should be performed in experienced centers.
Prognosis and follow-up
Non-seminomatous mediastinal EGCT have a poor prognosis with a 5-year OS of 40–45%, with inferior response rates to chemotherapy, especially in recurrence. The prognosis of retroperitoneal EGCT is better and similar to that of metastatic testicular GCT. The literature search for the follow-up of EGCT did not yield any relevant results. It is important to note that patients presenting with poor prognosis EGCT should be followed-up individually by specialized centers. The follow-up intervals of clinical examinations, ultrasound of the testicles, determination of tumor markers and radiological examinations (MRT/CT scans) should be similar to those of patients with metastatic GCT but must be adapted to the individual needs of the patient. EGCT patients have an increased risk for death from cardiovascular disease and those with mediastinal non-seminomas for the development of hematopoetic malignancies compared to testicular GCTs. These aspects need to be considered during follow-up. However, as many patients with EGCT can be long-term cured, they should be included into specific testicular cancer survivorship programs [10].
Discussion and conclusion
EGCTs are a very rare tumor entity with specific biological and clinical features. In the case of seminomatous histology, the prognosis is best represented by the IGCCCG classification, regardless of the location of the EGCTs, either in the mediastinum or retroperitoneum. However, the majority of EGCT patients have non-seminomatous components. Patients with retroperitoneal non-seminomatous EGCT should also be treated according to the IGCCCG risk classification. However, patients with mediastinal non-seminomatous EGCT are always classified as “very” poor prognosis. Upfront high-dose chemotherapy appears to be the best therapeutic option for these patients, since the chance of survival using an effective salvage chemotherapy in case of relapse is extremely low. Performing residual tumor resection (RTR) should be the standard procedure for non-seminomatous EGCT patients after initial chemotherapy, especially in patients suffering from mediastinal EGCTs, whenever technically feasible. Because of their poor prognosis and several potential clinical problems associated with the disease and treatment, these patients should be treated and followed-up in specialized centers.
Due to the rarity of EGCT cases, a detailed analysis in prospective randomized trials is hardly possible, so that the assessment of the best diagnostic and therapeutic options has to be based on retrospective studies.
The problem with the current systematic review is the lack of validated data from the last 10 years. Few statistically relevant studies in recent years could be identified, so important studies from earlier decades were also included in the review process.
Availability of data and material
Yes.
Code availability
None.
References
Schmoll HJ (2002) Extragonadal germ cell tumors. Ann Oncol 13(Suppl 4):265–272
Nichols CR et al (1987) Klinefelter’s syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5(8):1290–1294
Nichols CR et al (1985) Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med 102(5):603–609
Kliesch S et al (2021) Management of germ cell tumours of the testes in adult patients: German Clinical Practice Guideline, PART II—recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int 105(3–4):181–191
Durieux N, Vandenput S, Pasleau F (2013) OCEBM levels of evidence system. Rev Med Liege 68(12):644–649
Harbour R, Miller J (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323(7308):334–336
Hayden JA et al (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158(4):280–286
Guo B et al (2016) A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol 69:199-207 e2
Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
Alanee SR et al (2014) Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death. Urol Oncol 32(1):26 e9–15
Buchler T et al (2012) Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors. Klin Onkol 25(3):178–183
Necchi A et al (2015) A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal non-seminomatous germ cell tumors: the 27-year experience of a referral center. Clin Genitourin Cancer 13(1):87-93 e1
Rivera C et al (2010) Prognostic factors in patients with primary mediastinal germ cell tumors, a surgical multicenter retrospective study. Interact Cardiovasc Thorac Surg 11(5):585–589
De Latour B et al (2012) Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers. Eur J Cardiothorac Surg 42(1):66–71 (discussion 71)
Dechaphunkul A et al (2016) Clinical characteristics and treatment outcomes of patients with primary mediastinal germ cell tumors: 10-years’ experience at a single institution with a bleomycin-containing regimen. Oncol Res Treat 39(11):688–694
Liu TZ et al (2011) Treatment strategies and prognostic factors of patients with primary germ cell tumors in the mediastinum. J Cancer Res Clin Oncol 137(11):1607–1612
Sarkaria IS et al (2011) Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center. J Thorac Oncol 6(7):1236–1241
Rodney, A.J., et al., Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol, 2012. 30(6): p. 879–85.
Busch J, Seidel C, Zengerling F (2016) Male extragonadal germ cell tumors of the adult. Oncol Res Treat 39(3):140–144
Stang A et al (2012) Gonadal and extragonadal germ cell tumours in the United States, 1973–2007. Int J Androl 35(4):616–625
Rusner C et al (2013) Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998–2008. Cancer Epidemiol 37(4):370–373
Pauniaho SL et al (2012) The incidences of malignant gonadal and extragonadal germ cell tumors in males and females: a population-based study covering over 40 years in Finland. Cancer Causes Control 23(12):1921–1927
Moran CA, Suster S (1997) Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging. Cancer 80(4):681–690
McKenney JK, Heerema-McKenney A, Rouse RV (2007) Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 14(2):69–92
Kliesch S et al (2021) Management of germ cell tumours of the testis in adult patients. German Clinical Practice Guideline Part I: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages. Urol Int 105(3–4):169–180
Bokemeyer C et al (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 20(7):1864–1873
Moran CA, Suster S, Koss MN (1997) Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum—a clinicopathologic and immunohistochemical study of 64 cases. Cancer 80(4):699–707
Scholz M et al (2002) Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol 13(1):121–124
Rescorla FJ et al (1998) Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 33(2):171–176
Albany C, Einhorn LH (2013) Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol 25(3):261–265
Nichols CR (1991) Mediastinal germ cell tumors. Clinical features and biologic correlates. Chest 99(2):472–479
Bagrodia A et al (2016) Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol 34(33):4000–4007
Hartmann JT et al (2000) Hematologic disorders associated with primary mediastinal non-seminomatous germ cell tumors. J Natl Cancer Inst 92(1):54–61
Hartmann JT et al (2001) Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93(22):1733–1738
International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2):594–603
Mikuz G (2017) Germ cell and sex cord-stromal tumors of the testis: WHO classification 2016. Pathologe 38(3):209–220
Gillessen S et al (2021) Predicting outcomes in men with metastatic non-seminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol 39(14):1563–1574
Kollmannsberger C et al (2000) Identification of prognostic subgroups among patients with metastatic “IGCCCG poor-prognosis” germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 11(9):1115–1120
Hainsworth JD et al (1982) Advanced extragonadal germ-cell tumors. Successful treatment with combination chemotherapy. Ann Intern Med 97(1):7–11
Hidalgo M et al (1997) Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol 8(6):555–559
Goss PE et al (1994) Extragonadal germ cell tumors. A 14-year Toronto experience. Cancer 73(7):1971–1979
Ganjoo KN et al (2000) Results of modern therapy for patients with mediastinal non-seminomatous germ cell tumors. Cancer 88(5):1051–1056
Bokemeyer C et al (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 91(7):1394–1401
Bokemeyer C et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17(11):3450–3456
Ganjoo KN et al (2001) Germ cell tumor associated primitive neuroectodermal tumors. J Urol 165(5):1514–1516
Hartmann JT et al (2001) Second-line chemotherapy in patients with relapsed extragonadal non-seminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 19(6):1641–1648
Funding
Open Access funding enabled and organized by Projekt DEAL. None.
Author information
Authors and Affiliations
Contributions
Protocol/project development: CW, SS, PA, SK. Data collection or management: CW, SS, JL. Data analysis: CW, SS, JL, CB. Manuscript writing/editing: CW, SS, JH, FZ, JB, DP, CR, PA, SK, CB.
Corresponding author
Ethics declarations
Conflict of interest
This work is based on a clinical guideline program, which was funded by the German Cancer Aid Foundation (DKH) (Reference No. 70112789). All authors have no conflicts of interest to declare that are relevant to the content of this article.
Ethics approval
None.
Consent to participate
Yes.
Consent for publication
Yes.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Winter, C., Zengerling, F., Busch, J. et al. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. World J Urol 40, 2863–2878 (2022). https://doi.org/10.1007/s00345-022-04009-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-022-04009-z